Catalyst Brief

← Calendar

Readoutin 45d

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — TQB2102 for Injection

Phase 3 primary completion: A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer.

Date
Jan 2027
Type
Readout
Indication
Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  1. Dec2026
  2. Dec2026